Reviewer's report

Title: Clinical impact of B-cell depletion with the anti-CD20 antibody Rituximab in chronic fatigue syndrome: a preliminary case series

Version: 2 Date: 4 June 2009

Reviewer: A. Martin Lerner

Reviewer's report:

Minor Essential Revisions
1. What especial toxicity from rituximab in CFS patients was seen?
2. Shorten discussion by 1/2.

Minor Discretionary Revisions
1. The study would be strengthened by serum assays with titers for:
   EBV, VCA IgM - p18 peptide (with normal values)
   EBV, EA (diffuse) - 47 Kd peptide (with normal values)
   CMV IgG (with normal values)
   Human Herpesvirus 6 IgG (with normal values)
2. The study would be strengthened by quauntitating the severity of fatigue with the EIPS TM (Lerner AM, In Vivo 22:799-802,2008) e.g.Figures 1&2

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have no competing interests. I own with others patents concerning the diagnosis and treatment of CFS.